Cruise Pharmacia Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 07-12-2024
- Paid Up Capital ₹ 4.70 M
as on 07-12-2024
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 07-12-2024
- Revenue -59.96%
(FY 2016)
- Profit 138.22%
(FY 2016)
- Ebitda -839.51%
(FY 2016)
- Net Worth 0.04%
(FY 2016)
- Total Assets 36.47%
(FY 2016)
About Cruise Pharmacia
The Corporate was formerly known as Cruise Pharmecia Private Limited. The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.70 M.
The company currently has active open charges totaling ₹1.50 M.
Punit Jain, Sanjay Jain, Manu Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U52310PB2007PTC031411
- Company No.
031411
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Ludhiana, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cruise Pharmacia?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Jain  | Director | 11-Oct-2007 | Current |
| Punit Jain | Director | 11-Oct-2007 | Current |
| Manu Jain | Director | 11-Oct-2007 | Current |
| Tanuj Jain | Director | 11-Oct-2007 | Current |
Financial Performance of Cruise Pharmacia.
Cruise Pharmacia Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 59.96% decrease. The company also saw a substantial improvement in profitability, with a 138.22% increase in profit. The company's net worth moved up by a moderate rise of 0.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cruise Pharmacia?
In 2016, Cruise Pharmacia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cosmas Research Lab LimitedActive 16 years 7 monthsPunit Jain, Sanjay Jain and 2 more are mutual person
Cosmas Pharmacls LimitedActive 14 years 11 monthsPunit Jain, Sanjay Jain and 2 more are mutual person
Armour Remedies India LimitedActive 21 years 7 monthsPunit Jain, Sanjay Jain and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
United Bank Of India Creation Date: 31 Mar 2008 | ₹1.50 M | Open |
How Many Employees Work at Cruise Pharmacia?
Unlock and access historical data on people associated with Cruise Pharmacia, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cruise Pharmacia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cruise Pharmacia's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
